LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Leukemic Blood Test Has Massive Diagnostic Potential

By LabMedica International staff writers
Posted on 07 Sep 2016
Image: A photomicrograph of a leukemic cell and an extracellular vesicle (Photo courtesy of University of Manchester).
Image: A photomicrograph of a leukemic cell and an extracellular vesicle (Photo courtesy of University of Manchester).
The potential of a new test, which could revolutionize the way doctors diagnose and monitor common childhood leukemia, has been explored. The test is based on the fact that cancerous acute lymphoblastic leukemia cells produce and release special structures that can be traced in the blood.

The discovery could have major implications on the diagnosis, monitoring, drug delivery and treatment of childhood leukemia. Though there is an 85% to 90% success rate in treatment, children must endure repeat bone marrow biopsies to assess the progress of treatment. This discovery might reduce the frequency of the painful procedures, which can also cause bruising, bleeding and infection.

Scientists at the University of Manchester (UK) and their colleagues have investigated the use of extracellular vesicles, which were thought to be worthless debris, as a diagnostic biomarker. Their presence in the plasma from bone marrow biopsies was discovered their ability to circulate in the blood. The vesicles, which contain the protein actin and have identifiable characteristics of their parent cell, are typified by branching structures. The team also hopes that the vesicles might provide individualized information about the tumors, eventually helping doctors to deliver personalized care.

Suzanne M. Johnson, PhD, the lead author of the study, said, “Our discovery of Extracellular Vesicles could be a game changer in terms of the way we care for children with lymphoblastic leukemia. Our studies have shown that cancerous leukemia cells have the ability to package parts of themselves and then send these structures, the vesicles, to anywhere in the body though the blood. That opens up a world of possibilities in terms of monitoring the progress of the disease and making diagnosis quickly and efficiently. They are also internalized by other cells and act as an effective route for cell communication. Now the challenge is to investigate whether other cancers produce and release these structures as well.” The study was published on July 21, 2016, in the journal Blood.

Related Links:
University of Manchester

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more